GIMBHI’s daily mental health update — 07/15/26

🤝 Spero Health acquires CleanSlate, doubling footprint and averting shutdown (Chris Larson, Behavioral Health Business) — 07/07/26
TL;DR: Spero Health acquired opioid treatment provider CleanSlate Centers—saving it from closure—doubling Spero’s footprint to 128 locations across 10 states and preserving care for nearly 20,000 patients amid a tough addiction-treatment M&A market.

🧠 SAMHSA announces over $281M in grant funding for behavioral health initiatives (CADCA, LinkedIn) — 07/2026
TL;DR: SAMHSA announced more than $281M in grants supporting prevention, treatment, recovery, overdose response, suicide prevention, and behavioral health workforce initiatives nationwide.

🤝 Onebright acquires Mindstep to broaden workplace mental health offering (Emma Simon, Corporate Adviser) — 07/06/26
TL;DR: UK mental healthcare provider Onebright acquired digital platform Mindstep to create what it calls the UK’s first digitally-led, end-to-end workplace mental health and neurodevelopmental service, combining digital triage with clinical treatment.

🍄 From Schedule I to the clinic, insights into psychedelic drug development from GHB (Brian S. Barnett & Franklin King IV, JAMA Psychiatry) — 07/15/26
TL;DR: The authors use sodium oxybate’s (GHB-derived) FDA approval as a roadmap for psychedelic drug development, showing how Schedule I substances can navigate approval, scheduling, and strict REMS oversight into psychiatric practice.